

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2750544

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
CONVEYING PARTY DATA													
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>STEPHANE BANCEL</td> <td>02/07/2014</td> </tr> <tr> <td>TIRTHA CHAKRABORTY</td> <td>02/07/2014</td> </tr> <tr> <td>ANTONIN DE FOUGEROLLES</td> <td>02/07/2014</td> </tr> <tr> <td>SUSAN WHORISKEY</td> <td>02/07/2014</td> </tr> <tr> <td>RON WEISS</td> <td>02/26/2014</td> </tr> </tbody> </table>		Name	Execution Date	STEPHANE BANCEL	02/07/2014	TIRTHA CHAKRABORTY	02/07/2014	ANTONIN DE FOUGEROLLES	02/07/2014	SUSAN WHORISKEY	02/07/2014	RON WEISS	02/26/2014
Name	Execution Date												
STEPHANE BANCEL	02/07/2014												
TIRTHA CHAKRABORTY	02/07/2014												
ANTONIN DE FOUGEROLLES	02/07/2014												
SUSAN WHORISKEY	02/07/2014												
RON WEISS	02/26/2014												
RECEIVING PARTY DATA													
Name:	MODERNA THERAPEUTICS, INC.												
Street Address:	200 TECHNOLOGY SQUARE												
City:	CAMBRIDGE												
State/Country:	MASSACHUSETTS												
Postal Code:	02139												
PROPERTY NUMBERS Total: 1													
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>14107053</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	14107053								
Property Type	Number												
Application Number:	14107053												
CORRESPONDENCE DATA													
Fax Number:	(978)448-8721												
Phone:	9784488720												
Email:	docketing@dtwardlaw.com												
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>													
Correspondent Name:	DTWARD, PC												
Address Line 1:	142A MAIN STREET												
Address Line 4:	GROTON, MASSACHUSETTS 01450												
ATTORNEY DOCKET NUMBER:	2030.MNC2USCON3												
NAME OF SUBMITTER:	ANITA M. COSTA												

Signature:	/Anita M. Costa/
Date:	03/03/2014
<b>Total Attachments: 10</b> source=EXEC ASSIGNMENTS#page1.tif source=EXEC ASSIGNMENTS#page2.tif source=EXEC ASSIGNMENTS#page3.tif source=EXEC ASSIGNMENTS#page4.tif source=EXEC ASSIGNMENTS#page5.tif source=EXEC ASSIGNMENTS#page6.tif source=EXEC ASSIGNMENTS#page7.tif source=EXEC ASSIGNMENTS#page8.tif source=EXEC ASSIGNMENTS#page9.tif source=EXEC ASSIGNMENTS#page10.tif	

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/107,053 entitled "MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN", filed December 16, 2013.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


Title: MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN  
Filed: December 16, 2013  
Application No: 14/107,053

---

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date 2/7/14 Signature   
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Ron Weiss

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/107,053 entitled "MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN", filed December 16, 2013.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

Title: MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN  
Filed: December 16, 2013  
Application No: 14/107,053


---

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date 01/07/2014 Signature   
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougères

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Ron Weiss

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/107,053 entitled "MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN", filed December 16, 2013.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

Title: MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN  
Filed: December 16, 2013  
Application No: 14/107,053

---


INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date 7 Feb 2014 Signature   
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Ron Weiss



## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/107,053 entitled "MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN", filed December 16, 2013.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

Title: MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN  
Filed: December 16, 2013  
Application No: 14/107,053

---

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date 2/03/14 Signature   
Name Susan Whoriskey

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Ron Weiss

## ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Moderna Therapeutics, Inc. having a place of business at 200 Technology Square, Cambridge, MA 02139, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 14/107,053 entitled "MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN", filed December 16, 2013.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

Title: MODIFIED POLYNUCLEOTIDES ENCODING GRANULYSIN  
Filed: December 16, 2013  
Application No: 14/107,053

---

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Stephane Bancel

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Tirtha Chakraborty

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Antonin de Fougerolles

Date \_\_\_\_\_ Signature \_\_\_\_\_  
Name Susan Whoriskey

Date 2/26/2014 Signature   
Name Ron Weiss